High-throughput screening methodology to identify alpha-synuclein aggregation inhibitors by Pujols, Jordi et al.
 International Journal of 
Molecular Sciences
Article
High-Throughput Screening Methodology to Identify
Alpha-Synuclein Aggregation Inhibitors
Jordi Pujols 1,†, Samuel Peña-Díaz 1,†, María Conde-Giménez 2, Francisca Pinheiro 1,
Susanna Navarro 1,3, Javier Sancho 2 and Salvador Ventura 1,3,*
1 Department of Biochemistry and Molecular Biology, Autonomous University of Barcelona, 08193 Bellaterra,
Spain; jordi.pujolspujol@gmail.com (J.P.); samuel.pdiaz@gmail.com (S.P.-D.);
chicagpinheiro@outlook.pt (F.P.); susanna.navarro.cantero@uab.cat (S.N.)
2 Department of Biochemistry and Molecular and Cell Biology, Institute for Biocomputation and Physics of
Complex Systems (BIFI), University of Zaragoza, 50018 Zaragoza, Spain; maria.conde@gmail.com (M.C.-G.);
jsancho@unizar.es (J.S.)
3 Institute of Biotechnology and Biomedicine, Autonomous University of Barcelona, 08193 Bellaterra, Spain
* Correspondence: salvador.ventura@uab.cat; Tel.: +34-93-586-8956
† These authors contributed equally to this work.
Academic Editor: Irmgard Tegeder
Received: 15 December 2016; Accepted: 20 January 2017; Published: 2 March 2017
Abstract: An increasing number of neurodegenerative diseases are being found to be associated with
the abnormal accumulation of aggregated proteins in the brain. In Parkinson’s disease, this process
involves the aggregation of alpha-synuclein (α-syn) into intraneuronal inclusions. Thus, compounds
that inhibit α-syn aggregation represent a promising therapeutic strategy as disease-modifying agents
for neurodegeneration. The formation of α-syn amyloid aggregates can be reproduced in vitro by
incubation of the recombinant protein. However, the in vitro aggregation of α-syn is exceedingly
slow and highly irreproducible, therefore precluding fast high throughput anti-aggregation drug
screening. Here, we present a simple and easy-to-implement in-plate method for screening large
chemical libraries in the search for α-syn aggregation modulators. It allows us to monitor aggregation
kinetics with high reproducibility, while being faster and requiring lower protein amounts than
conventional aggregation assays. We illustrate how the approach enables the identification of strong
aggregation inhibitors in a library of more than 14,000 compounds.
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1. Introduction
Protein misfolding and amyloid aggregation is behind a growing number of human diseases,
including Parkinson’s disease (PD) [1]. PD is the second most common neurodegenerative disorder,
after Alzheimer’s disease (AD) and is still incurable. PD is characterized by protein deposition in
intraneuronal inclusions, the so-called Lewy bodies (LB) and Lewy neurites (LN) [2,3], whose major
component is α-synuclein (α-syn) [4], a 140 amino acid presynaptic protein encoded by the SNCA
gene and normally found in both soluble and membrane-associated fractions of the brain [5,6]. The
protein α-syn is a central component in PD pathogenesis and accordingly a privileged target for
therapeutic intervention. In vitro, under physiological conditions, α-syn assembles into aggregates
that are structurally similar to those found in the inclusions of disease-affected brains [7,8]. The
aggregation process is thought to start from soluble monomers that polymerise into ring-shaped
and string-like oligomers. These small structures coalesce to form protofibrils that assemble into
insoluble fibrils [9,10]. The precise nature of the toxic α-syn species is still unclear, although it is
believed that specific oligomeric species play a key role in neuronal toxicity, rather than the mature
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aggregates [11,12]. It is thought that the population of these small oligomeric species is also associated
with the spread of the disease between different structures in the brain [13,14].
There is strong interest in the discovery of small compounds that can act as chemical chaperones
modulating the aggregation of α-syn [15–20]. In the absence of a defined 3D-structure to target,
screening of large collections of chemically diverse compounds is a useful approach toward the
discovery of novel bioactive molecules exhibiting an α-syn anti-aggregational effect. Chemical
kinetics approaches would allow the quantitative detection of the effects of potential therapeutic
molecules on aggregation [21]; however, the application of this type of analysis is hampered by the
low reproducibility of aggregation reactions, resulting in dissimilar kinetic parameters and/or high
errors even within replicates in the same aggregation assay. This is especially true for α-syn, a protein
displaying a very slow aggregation reaction, usually taking several days, which is highly influenced
by factors like pH, temperature, agitation or the presence of impurities [18–20,22–31]. The lack of
reproducibility between aggregation curves is a strong limitation to identify bona fide aggregation
inhibitors, since their potency becomes hidden in overlapping errors bars, especially at the beginning of
the reaction, where the more toxic oligomeric species are expected to be formed. The slow aggregation
kinetics of α-syn is also an important time limitation for large-scale screening, where several thousands
of potential inhibitors should be tested. Due to the dependence of the reaction on the initial protein
concentration, the aggregation of α-syn can be accelerated by increasing this parameter. However, this
means that very large amounts of protein will be necessary for high-throughput screening assays.
The aim of the present work is to provide a detailed aggregation kinetics protocol suitable for the
large-scale screening of aggregation modulators that can be used without requiring extensive previous
expertise in protein aggregation and/or in the manipulation of α-syn. By ensuring a high purity of
the recombinant protein and performing protein aggregation assays in 96-well plates in presence of
teflon polyballs, the fibrillation reaction is boosted, requiring times and protein quantities that are
compatible with high-throughput screening. After optimizing agitation and temperature, we obtained
highly reproducible kinetics that allowed us to derivate accurate aggregation constants. We illustrate
how the approach permitted the identification of strong inhibitors after screening a library of more
than 14,000 compounds.
2. Results
2.1. Protein Expression and Purification
For protein expression and purification, we adapted a protocol from Volles and Lansbury [32],
including an additional sonication step during cell lysis and, more importantly, a final anion exchange
chromatography (Figure 1). This purification step is crucial, since not only does it increase homogeneity,
but also avoids9 the co-elution of nucleic acids. α-Syn binds to nucleic acids, the concentrations and
identities of which might vary from preparation to preparation. Because most labs monitor the
purity of their α-syn preparations using SDS-PAGE (Sodium Dodecyl Sulfate Polyacrylamide Gel
Electrophoresis) and protein staining, nucleic acids are not visualized. The use of spectrophotometry
to discard nucleic acid contaminations is highly advisable, since, in our hands, their presence results in
a large heterogeneity in the kinetics of aggregation reactions.
Following this protocol, we obtained high amounts of nucleic acid free α-syn (35 mg/L culture).
Purity of α-syn was checked by SDS-PAGE (Figure 2) and mass spectrometry, obtaining a band
and a peak that corresponds to the theoretical weight of α-syn, respectively, without any trace of
contaminant proteins.
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Figure 1. General strategy for the purification of α-synuclein. Figure 1. General strategy for the purification of α-synuclein.
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Figure 2. SDS-PAGE of the expression, fractionation and purification process. −IPTG and +IPTG 
(isopropyl β-D-1-thiogalactopyranoside) lines correspond to-non induced and induced cell extracts. 
The insoluble and soluble fractions of induced cells are shown as well as different fractions eluting 
from the anion exchange column. 
2.2. Aggregation Kinetics 
One of the most important hallmarks of α-syn aggregation is the long time it needs to be 
completed. When compared with other amyloid-forming proteins, the time required for the assembly 
of detectable mature fibrils is significantly longer, in such a way that at concentrations below 100 μM, 
the reaction exhibits a large lag phase, is only completed in one or more weeks and displays low 
reproducibility [18]. Because the aggregation ratios are extremely dependent on the initial protein 
concentration, the aggregation of α-syn has usually been accelerated by dramatically increasing its 
concentration in the assay, up to 400 μM. High concentration also reduces erratic fibrillation [9]. 
However, the drawback is that very large amounts of protein are necessary for large-scale screening 
(0.75 mg of α-syn for a single 150 μL reaction at 400 μM) [23,24].  
Here we present a protocol, in which, despite the use of concentrations of purified α-syn < 100 
μM, the sigmoidal aggregation reactions are completed in approx. 24 h. To track the aggregation 
progress, we took advantage of the amyloid specific reporter Th-T (Thioflavin-T), added to each 
sample at 40 μM as final concentration. One of the main problems when performing kinetics is the 
loss of the mixture homogeneity as the reaction progresses. Most of the assays are performed on 
Eppendorf or glass tubes, from where aliquots are removed at certain times and diluted for 
fluorescence measurements in a quartz cuvette. Dilutions do not necessarily represent the original 
species population, and even when samples are sonicated or re-mixed, it is impossible to predict how 
representative the amount of aggregate is that we are taking out from the solution. To reduce 
variability, caused by both sample manipulation and aggregates heterogeneity, in our case, 
measurements were directly recorded in a 96-well plate (black plastic) using a plate reader. 
Agitation has been shown to accelerate α-syn aggregation up to 1 order of magnitude. The effect 
of the agitation is implicitly or explicitly attributed to mass transfer or fibril fragmentation. However, 
for α-syn, despite agitation with only air resulting in somewhat accelerated kinetics, in our hands, 
the reactions were inconsistent from well to well and even resulted in different aggregates 
morphology. The use of glass beads during agitation potentially increases the air–water interface 
area; however, their effect on the speed and reproducibility of the reaction is controversial [33,34]. 
Investigations have demonstrated the sensitivity of aggregation reactions to hydrophobic-water 
interfaces and in particular to teflon-water interfaces [35] and indeed teflon beads have been used in 
a number of α-syn aggregation studies [36,37]. Therefore, we incorporated a teflon bead (2 mm 
diameter) in each well and incubated the plates under continuous agitation in an orbital shaker, since 
it provides more homogeneous ball agitation than a linear one. The presence of these little spheres 
accelerated dramatically the kinetics of α-syn aggregation, allowing us to work with 70 μM α-syn in 
a final sample volume of 150 μL, thus reducing the amount of protein needed per reaction (0.145 
mg/well). No aggregates were observed to form at the same protein concentration and conditions 
during the first 24 h in the absence of mixing balls, whereas in their presence, typical long unbranched 
amyloid fibrils could be observed by TEM (Transmission Electron Microscopy) (Figure 3). 
Figure 2. SDS-PAGE of the expressi , f ctionation and purification process. −IPTG and +IPTG
(isopropyl β-D-1-thiogalactopyranoside) lines c to-non induced and induced cell extracts.
The insoluble and soluble fractions of induced cells are shown as well as different fractions eluting
from the anion exchange column.
2.2. Aggregation Kinetics
One of the most important hallmarks ofα-syn aggregation is the long time it needs to be completed.
When compared with other amyloid-forming proteins, the time required for the assembly of detectable
mature fibrils is significantly longer, in such a way that at concentrations below 100 µM, the reaction
exhibits a large lag phase, is only completed in one or more weeks and displays low reproducibility [18].
Because the aggregation ratios are extremely dependent on the initial protein concentration, the
aggregation of α-syn has usually been accelerated by dramatically increasing its concentration in the
assay, up to 400 µM. High concentration also reduces erratic fibrillation [9]. However, the drawback s
tha very large amounts of protein are necessary for large-scale screening (0.75 mg of α-syn or a single
150 µL reaction at 400 µM) [23,24].
Here we present a protocol, in which, despite the use of concentrations of purified α-syn < 100 µM,
the sigmoidal aggregation reactions are completed in approx. 24 h. To track the aggregation progress,
we took advantage of the amyloid specific reporter Th-T (Thioflavin-T), added to each sample at 40 µM
as final concentration. One of the main problems when performing kinetics is the loss of the mixture
homogeneity as the reaction progresses. Most of the assays are performed on Eppendorf or glass
tubes, from where aliquots are removed at certain times and diluted for fluorescence measurements
in a quartz cuvette. Dilutions do not necessarily represent the original species population, and even
when samples are sonicated r re-mixed, it is impossible to predict how representative the amount of
aggregate is that we are taking o t from th solution. To re uce variability, caused by both sample
manipulation and aggregates heterogeneity, in our s , measurements were directly r corded in a
96-well plate (black plastic) using a plate reader.
Agitation has been shown to accelerate α-syn aggregation up to 1 order of magnitude. The effect
of the agitation is implicitly or explicitly attributed to mass transfer or fibril fragmentation. However,
for α-syn, despite agitation with only air resulting in somewhat accelerated kinetics, in our hands, the
reactions were inconsistent from well to well and even resulted in different aggregates morphology.
The use of glass beads during agitation potentially increases the air–water interface area; however,
their effect on the speed and reproducibility of the reaction is controversial [33,34]. Investigations have
demonstrated the sensitivity of aggregation reactions to hydrophobic-water interfaces and in particular
to teflon-water interfaces [35] and indeed teflon beads have been used in a number of α-syn aggregation
studies [36,37]. Th refore, we incorporated a teflon bead (2 mm diameter) in each well and incubated
the plates under continuous gitation in a orbital shaker, since it provides more homogeneous ball
agitation than a linear one. The presence of these little spheres accelerated dramatically the kinetics of
α-syn aggregation, allowing us to work with 70 µM α-syn in a final sample volume of 150 µL, thus
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reducing the amount of protein needed per reaction (0.145 mg/well). No aggregates were observed to
form at the same protein concentration and conditions during the first 24 h in the absence of mixing
balls, whereas in their presence, typical long unbranched amyloid fibrils could be observed by TEM
(Transmission Electron Microscopy) (Figure 3).Int. J. Mol. Sci. 2017, 18, 478 5 of 12 
 
 
Figure 3. α-Synuclein fibrils formed in the presence of teflon beads. TEM images were collected upon 
incubation of 70 μM soluble α-syn for 24 h with agitation in the presence of beads. The samples were 
briefly sonicated before imaging.  
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reader itself to incubate the plates one by one. In this way, we can achieve a smooth, prolonged and 
continuous agitation, in contrast to the short and intermittent one (commonly only 15 s before each 
measure) performed by conventional plate readers. Moreover, it is possible to accurately adjust the 
temperature (37 °C) and agitation conditions (100 rpm), enabling us to acquire well-to-well and plate-
to-plate reproducible aggregation curves. Plates are only pulled out from the incubator for 
fluorescence reads and rapidly returned to their original location. Together, the method reduces both 
protein concentration and aggregation times, abolishes most sample manipulation, allows for 
simultaneous assays and maximizes reproducibility (Figure 4A). The accuracy of the protocol can be 
observed in Figure 4B, where it is shown how plotting Th-T fluorescence signal as a function of time 
for two different aggregation reactions, recorded in non-consecutive days, results in sigmoidal curves 
that overlap almost perfectly. In this way, when k1 (nucleation rate constant) and k2 (growth rate 
constant) were calculated using the Finke-Watzky two-step model for the two curves [38] we 
obtained k11 = 0.00640 ± 0.0013 h−1, k12 = 0.00645 ± 0.0016 h−1 and k21 = 0.3623 ± 0.0264 h−1, k22 = 0.3365 
± 0.0336 h−1, with correlation coefficients R > 0.998, in both cases. As expected, the relative standard 
error is larger for k1 than for k2, indicating that nucleation is inherently more stochastic than 
elongation. This is the reason why the use of preformed amyloid seeds usually results in highly 
reproducible kinetics [39]; however, this precludes the identification of compounds that target the 
nucleation phase of amyloid formation. 
The applicability of this methodology was validated by screening a large chemical library. We 
used the Maybridge HitFinder Collection, containing 14,400 compounds, in the search for putative 
inhibitors of α-syn aggregation. Each compound was tested in triplicate and each plate contained a 
triplicated α-syn control devoid of compound. Discarding false positives caused by Th-T fluorescence 
quenching during the data collection was essential. For this purpose, we recorded the absorbance 
spectra from 400 to 600 nm for any putative positive compound, and discarded those absorbing either 
at the Th-T excitation or emission wavelengths, 450 and 480 nm respectively. The successfulness of 
the approach is illustrated in Figure 4C, with two compounds (D and G) that exhibit medium and 
high effect on final Th-T fluorescence. It can be observed the low error bars obtained for all the 
reactions, which results in high statistical significance when assessing the inhibitory potency of the 
compounds at any time point. Accordingly, fitting the experimental data to the Finke-Watzky curve 
resulted in the large majority of cases in correlation coefficients R > 0.985. The ability of the method 
to identify bona fide inhibitors requires an orthogonal validation. In our case it was confirmed by 
visualizing control and compound-treated reactions end points by TEM. As an example, it can be 
seen in Figure 4D–F how the presence of compounds D and G results in an important decrease in 
both number and size of α-syn fibrils. Centrifugation assays indicated higher levels of soluble α-syn 
at the end of the reaction in the presence of inhibitors. The screening rendered 47 novel compounds 
Figure 3. α-Synuclein fibrils formed in the presence of teflon beads. TEM images were collected upon
incubation of 70 µM soluble α-syn for 24 h with agitation in the presence of beads. The samples were
briefly sonicated before imaging.
One remarkable advantage of the r t c l is t e capacity to simultaneously handle a high
number of plates by fixing them on a conventional orbital culture incubator, instead of using
the plate reader itself to incubate the plates one by one. In this way, we can achieve a smooth,
prolonged and continuous agitation, in contrast to the short and intermittent one (commonly only
15 s before each measure) performed by conventional plate readers. Moreover, it is possible to
accurately adjust the temperature (37 ◦C) and agitation conditions (100 rpm), enabling us to acquire
well-to-well and plate-to-plate reproducible aggregation curves. Plates are only pulled out from the
incubator for fluorescence reads and rapidly returned to their original location. Together, the method
reduces both protein concentration and aggregation times, abolishes most sample manipulation,
allows for simultaneous assays and maximizes reproducibility (Figure 4A). The accuracy of the
protocol can be observed in Figure 4B, where it is shown how plotting Th-T fluorescence signal
as a function of time for two different aggregation reactions, recorded in non-consecutive days,
results in sigmoidal curves that overlap almost perfectly. In this way, when k1 (nucleation rate
constant) and k2 (growth rate constant) were calculated using the Finke-Watzky two-step model
for the two curves [38] we obtained k11 = 0.00640 ± 0.0013 h−1, k12 = 0.00645 ± 0.0016 h−1 and
k21 = 0.3623 ± 0.0264 h−1, k22 = 0.3365 ± 0.0336 h−1, with correlation coefficients R > 0.998, in both
cases. As expected, the relative standard error is larger for k1 than for k2, indicating that nucleation
is inherently m e stoc stic than elongatio . This is the reas why the use of preformed amyloid
seeds usually results in highly reproducible kinetics [39]; however, this precludes the identification of
compounds that target the nucleation phase of amyloid formation.
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and the activities of 10 representative molecules are illustrated in Table 1. After fitting their respective 
aggregation curves, the 47 compounds fall into one of two classes: those that decrease the final Th-T 
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exhibit pharmacological interest, since they are expected to delay the onset of the aggregation 
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fluorescence emission, represented as normalised means. Error bars are represented as standard error. 
(D–F) TEM images of α-synuclein fibrils in absence (D) and presence of inhibitors (D–G). 
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plate preparation and incubation; (B) α-synuclein aggregation kinetics performed on non-consecutive
days; (C) α-synuclein aggregation kinetics in presence of putative inhibitors. Measured by Th-T
fluorescence emission, repre e ted as normalised means. Error bars are represented as standard error.
(D–F) TEM images of α-synuclein fibrils in absence (D) and presence of inhibitors (D–G).
The applicability of this methodology was validated by screening a large chemical library. We used
the Maybridge HitFinder Collection, containing 14,400 compounds, in the search for putative inhibitors
of α-syn aggregation. Each compound was tested in triplicate and each plate contained a triplicated
α-syn control devoid of compound. Discarding false positives caused by Th-T fluorescence quenching
during the data collection was essential. For this purpose, we recorded the absorbance spectra from
400 to 600 nm for any putative positive compound, and discarded those absorbing either at the Th-T
excitation or emission wavelengths, 450 and 480 nm respectively. The successfulness of the approach
is illustrated in Figure 4C, with two compounds (D and G) that exhibit medium and high effect on
final Th-T fluorescence. It can be observed the low error bars obtained for all the reactions, which
results in high statistical significance when assessing the inhibitory potency of the compounds at
any time point. Accordingly, fitting the experimental data to the Finke-Watzky curve resulted in the
large majority of cases in correlation coefficients R > 0.985. The ability of the method to identify bona
fide inhibitors requires an orthogonal validation. In our case it was confirmed by visualizing control
and compound-treated reactions end points by TEM. As an example, it can be seen in Figure 4D–F
how the presence of compounds D and G results in an important decrease in both number and size
of α-syn fibrils. Centrifugation assays indicated higher levels of soluble α-syn at the end of the
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reaction in the presence of inhibitors. The screening rendered 47 novel compounds able to efficiently
modulate the aggregation and inhibit fibril formation of α-syn. These compounds belong to different
chemical families, supporting the versatility of the assay. The chemical structures and the activities of
10 representative molecules are illustrated in Table 1. After fitting their respective aggregation curves,
the 47 compounds fall into one of two classes: those that decrease the final Th-T fluorescence without
reducing k1 and k2, like compound G, and those that decrease both the fluorescence signal and the
kinetic constants, like compound D. They are those last compounds that exhibit pharmacological
interest, since they are expected to delay the onset of the aggregation reaction. A convenient way to
discriminate between these two types of molecules in large-screening assays is to compare the halftime
of aggregation (t50) [40].
Table 1. Representative active compounds identified in the high-throughput screening.
Name Code Structure % Inhibition a t50 (h) b
N-(1-benzothiophen-2-yl)-N′-
[3,5-bis(trifluoromethyl)phenyl]urea A
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The present method not only provides an effective system for screening, but can be used to set up
a variety of experiments. For instance, when developing new anti-aggregational drugs, it is essential to
titrate their concentration-dependent activity. Many promising potential drugs fail because they are not
effective at a concentration compatible with their pharmaceutical application. The high reproducibility
of the method allows us to perform accurate titration assays, as illustrated for compound D in Figure 5
where a clear dose-dependent anti-aggregation activity could be tracked for this molecule, which turns
out to be active even at sub-stoichiometric protein:compound ratios. However, we should clarify that
the method only allows us to detect α-syn species that can be stained with Th-T and thus it fails to
monitor the impact of the compounds in the formations of early oligomers.
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Figure 5. Inhibition of α-synuclein aggregation at different concentrations of the compound D. Error 
bars are represented as standard error, where p < 0.005 and p < 0.0005 were indicated by ** and *** 
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3. Discussion 
The present work provides a simple and accurate method for screening large chemical libraries 
in the search of lead compounds with the potential to become enrolled in future treatments for PD. It 
is conceived as a friendly-to-use, easy-to-implement, protocol for non-specialized research labs, with 
the aim of reducing both time and resources, without losing accuracy. It allows us to monitor 
aggregation kinetics with high reproducibility and low errors, permitting to identify true positives 
among large collections of putative candidates and, in addition, assessing specific drug features such 
as the mechanism of action or the concentration and time dependence of the compound activity. 
Despite it is true that compounds able to inhibit in vitro α-syn in the presence of teflon polyballs 
would not necessarily behave in the same manner in vivo and thus that they are still far from being 
biologically effective therapeutics for synucleinopathies, the possibility to recruit novel labs in the 
search for such molecules, without the need for an initial large investment in specialized equipment, 
would likely boost the finding of novel candidates with the potential to halt the onset or the 
progression of these devastating disorders. 
4. Materials and Methods 
4.1. Expression and Purification of Human α-Synuclein 
Human α-synuclein was expressed and purified adapting a previous protocol from Volles and 
Lansbury [32]. Escherichia coli BL21 (DE3) cells were transformed with a pET21a plasmid (Novagen, 
EMD-Millipore, Darmstadt, Germany) containing the α-syn cDNA, grown in LB medium containing 
100 μM/mL ampicillin and induced with 1 mM IPTG for 4 h at an optical density at 600 nm of 0.6. 
After cell centrifugation at 7000× g for 10 min at 4 °C, the pellet was resuspended in 20 mL Phosphate 
Buffered Saline (PBS) buffer, centrifuged again at 4000× g for 20 min at 4 °C and frozen at −80 °C. 
When needed, the pellets were defrosted and resuspended in 10 mL lysis buffer (50 mM Tris pH 8, 
150 mM NaCl, 1 μg/mL pepstatin, 20 μg/mL aprotinin, 1 mM benzamidine, 1mM PMSF, 1 mM EDTA 
Figure 5. Inhibition of α-synuclein aggregation at different concentrations of the compound D. Error
bars are represented as standard error, where p < 0.005 and p < 0.0005 were indicated by ** and
*** respectively.
3. Discussion
The present work provides a simple and accurate method for screening large chemical libraries
in the search of lead compounds with the potential to become enrolled in future treatments for PD.
It is conceived as a friendly-to-use, easy-to-implement, protocol for non-specialized research labs,
with the aim of reducing both time and resources, without losing accuracy. It allows us to monitor
aggregation kinetics with high reproducibility and low errors, permitting to identify true positives
among large collections of putative candidates and, in addition, assessing specific drug features such as
the mechanism of action or the concentration and time dependence of the compound activity. Despite
it is true that compounds able to inhibit in vitro α-syn in the presence of teflon polyballs would not
necessarily behave in the same manner in vivo and thus that they are still far from being biologically
effective therapeutics for synucleinopathies, the possibility to recruit novel labs in the search for such
molecules, without the need for an initial large investment in specialized equipment, would likely
boost the finding of novel candidates with the potential to halt the onset or the progression of these
devastating disorders.
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4. Materials and Methods
4.1. Expression and Purification of Human α-Synuclein
Human α-synuclein was expressed and purified adapting a previous protocol from Volles and
Lansbury [32]. Escherichia coli BL21 (DE3) cells were transformed with a pET21a plasmid (Novagen,
EMD-Millipore, Darmstadt, Germany) containing the α-syn cDNA, grown in LB medium containing
100 µM/mL ampicillin and induced with 1 mM IPTG for 4 h at an optical density at 600 nm of 0.6.
After cell centrifugation at 7000× g for 10 min at 4 ◦C, the pellet was resuspended in 20 mL Phosphate
Buffered Saline (PBS) buffer, centrifuged again at 4000× g for 20 min at 4 ◦C and frozen at −80 ◦C.
When needed, the pellets were defrosted and resuspended in 10 mL lysis buffer (50 mM Tris pH 8,
150 mM NaCl, 1 µg/mL pepstatin, 20 µg/mL aprotinin, 1 mM benzamidine, 1mM PMSF, 1 mM
EDTA and 0.25 mg/mL lysozyme) prior to sonication using a LabSonic®U sonicator (B. Braun Biotech
International, Melsungen, Hessen, Germany) with a power level of 40 W and a repeating duty cycle
of 0.7 s for 3 intervals of 3 min. Resultant cell extract was boiled at 95 ◦C for 10 min and centrifuged
at 20,000× g for 40 min at 4 ◦C. To the obtained supernatant 136 µL/mL of 10% w/v streptomycin
sulfate and 228 µL/mL of pure acid acetic were added and centrifuged at 4 ◦C (20,000× g, 10 min).
The resulting soluble fraction was diluted with saturated ammonium sulfate (550 g/L) 1:1 (v/v) and
centrifuged at 4 ◦C (20,000× g, 10 min). Then, the pellet was resuspended in 50% ammonium sulfate
and centrifuged at 4 ◦C (20,000× g, 10 min). The pellet was washed with 100 mM pH 8 ammonium
acetate (5 mL per culture litre) and pure EtOH 1:1 (v/v), then, the mixture was centrifuged at 4 ◦C
(20,000× g, 10 min). The pellet was resuspended in 20 mM pH 8 Tris and filtered with a 0.45 mm filter.
Anion exchange column HiTrap Q HP was coupled to an ÄKTA purifier high performance liquid
chromatography system in order to purify α-synuclein. Tris 20 mM pH 8 and Tris 20 mM pH 8, NaCl
1 M were used as buffer A and buffer B respectively. After column equilibration with buffer A, sample
was injected by using a Pump Direct Loading P-960 and the weak bonded proteins were washed with
5 column volumes (cv) of Buffer A. To properly isolate α-syn, a step gradient was applied as follows:
(i) 0%–20% buffer B, 5 cv; (ii) 20%–45% buffer B, 11 cv; (iii) 100% buffer B, 5 cv, obtaining pure α-syn
between 25% and 35% buffer B concentration. The collected peaks were dialyzed in 5 L ammonium
sulfate 50 mM overnight. α-Syn concentration was determined measuring the absorbance at 280 nm
and using the extinction coefficient 5960 M−1·cm−1. Purity was checked using 15% SDS-PAGE and
unstained Protein Standard markers from Thermo Fisher Scientific. The gel was stained with comassie
brilliant blue. Identity was checked by mass spectrometry. 2 µL of protein were dialyzed for 30 min
at room temperature using 20 mL of 50 mM ammonic bicarbonate and a 0.025 µm pore membrane
(EMD-Millipore, Darmstadt, Germany). After that, MALDI-TOF was analysis was performed with a
ground steel plate and 2,6-dihidroxiacetophenone acid as a matrix, in a MALDI-TOF UltrafleXtreme
(Bruker Daltonics, Billerica, MA, USA). A 1:1 sample:matrix mixture was used, adding just 1 µL of
these sample to the plate. For the analysis, a lineal mode was used with an accelerated voltage of 25 kV.
Finally, after lyophilisation, the protein was kept at −80 ◦C.
4.2. Quenching Analysis of Compounds
The different compounds were dissolved at 50 mM in pure 100% DMSO solution. In order
to check the interference of the compounds with thioflavin-T (Th-T) excitation or emission, the
absorption spectra for each compound at 100 µM was measured from 400 to 600 nm in a
spectrophotometer Cary100.
4.3. α-Synuclein Aggregation and Thioflavin-T Assays
Previously lyophilised α-synuclein was carefully dissolved in PBS buffer to a final concentration
of 210 µM and filtered through a Millipore s 0.22-µm filters. α-syn aggregation assay was performed
in a 96 wells plate (non-treated, black plastic) containing in each well a teflon polyball (1/8′ ′ diameter),
40 µM thiofalvin-T, 70 µM α-synuclein, 100 µM of the tested compounds and PBS up to a final
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volume of 150 µL. Plates were fixed into an orbital culture shaker Max-Q 4000 Thermo Scientific
(Waltham, MA, USA) to keep the incubation at 37 ◦C, 100 rpm. Every 2 h, the fluorescence intensity
was measured using a Victor3.0 Multilabel Reader, PerkinElmer (Waltham, MA, USA) by exciting
the mixtures with 430–450 filter and collecting the emission intensity with 480–510 filter (triplicates
for each measurement). Each plate contained 3 α-syn controls in the absence of any compound. The
averaged Th-T fluorescence obtained for these wells at the end of the experiment was normalized to
1 and the kinetic curves in the different wells re-scaled accordingly. Re-scaled curves were used to
compare the controls with the effect of compounds and to ensure that the controls were reproducible
between different experiments.
For the titration assay the following concentrations for all selected compounds (200, 150, 100,
75 and 25 µM) were used.
4.4. Transmission Electron Microscopy (TEM)
α-Synuclein fibers from final point reaction (either in absence or presence of the final concentration
inhibitors) were collected and after diluting the aggregated α-syn to a concentration of 10 µM
α-synuclein, each sample was sonicated for 10 min. A volume of 5 µL of these samples were placed
on carbon-coated copper grids and allowed them to stand for 5 min. Then, samples were carefully
dried with filter paper to remove the excess of sample. Grids were washed twice with MiliQ water
by immersion and stained by incubating grids with 5 µL 2% (w/v) uranyl acetate for 2 min for the
negative staining. After removal of the uranyl acetate excess with filter paper, grids were left to air-dry
for 10 min. The samples were imaged using a Transmission Electron Microscopy Jeol 1400, JEOL
(Peabody, MA, USA) operating at an accelerating voltage of 120 kV. At least 30 fields were screened, to
obtain representative images.
4.5. Statistical Analysis
Data were analysed by ANOVA Tukey test using SPSS software version 20.0 (IBM Analytics,
Armonk, NY, USA). All data are shown as means and standard error. p < 0.05 was considered
statistically significant and indicated by ** and *** if p < 0.005 and p < 0.0005, respectively.
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